There’s a huge, worldwide demand for a post-surgery scar reducing drug. Scar revision surgery is the third most common reconstructive procedure performed in the USA according to the American Society for Aesthetic and Plastic Surgeons. Will the new, soon to be launched Juvista fill this gap in the market?
Juvista is a drug that would be injected intradermally into the margins of wounds created by cosmetic and reconstructive plastic surgeons during scar revision surgery.
The manufacturer of Juvista, pharmaceutical company Renovo said that the phase III trial for scar revision drug Juvista is nearly complete.
As scars to be revised occur at all sites within the body (head, neck, limbs, chest, abdomen, back), in all races, sexes and in a wide age range, Renovo will seek to generate safety and efficacy data for Juvista across a wide range of body sites and patients.
Juvista has currently been tested on more than 1,500 patients. As for now the clinical trials have brought to light two failures of Juvista – in mole removal and breast augmentation. Juvista is the commercial name for the drug Avotermin – an injectable solution of human active recombinant transforming growth factor beta 3 (TGFβ3).
Apart from scar revision there are all sorts of other potential uses, from varicose vein treatment to cosmetic surgery.
“Juvista has the potential to become standard of care to reduce scaring after surgery work the high sales potential validated by Shire’s interest in the North American rights.”
Its main focus is to continue developing its scar-reduction treatments Juvista and Prevascar, with the results of clinical trials expected in the first half of this year.
Update: Failure Juvista Clinical Trial
Too bad but the clinical trial for anti-scarring drug Juvista did not meet primary or secondary endpoints. The Renovo companay is completing trials of two other treatments, Prevascar and Adaprev.
More info on the Renovo website.